Anifrolumab and risk study for lupus patients
Treatments studied
Part of Cancer, Immune system & allergy, Infections, Skin clinical trials.
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe lupus (SLE).
- You must have had at least one lupus flare in the last 6 months.
- You haven't had a prescription for anifrolumab before.
- You are at least 18 years old.
- No history of cancer, HIV/AIDS, organ transplant, or serious infection in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.
This study tests an experimental drug called anifrolumab, which is given as an injection or infusion, to see how it works in people with active lupus. It may help reduce lupus symptoms by targeting the immune system.
This study tests whether anifrolumab, a drug that targets the immune system, can improve markers of blood vessel health in people with lupus. It may help reduce the risk of heart problems associated with lupus.
This study is looking at how the lupus medicine anifrolumab passes into breast milk and affects mothers and their babies. It is for women who are already taking anifrolumab for lupus and are breastfeeding a baby born at 32 weeks or later.
This study collects information on pregnancy outcomes in women who took the drug anifrolumab during pregnancy or within 16 weeks before conception. It helps researchers understand how the drug may affect pregnancy and the baby.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.